Evogene Evogene
Toggle navigation
  • Company
  • Technology
  • AI Tech-Engines
  • Licensing & Collaboration
  • ESG
    • Environmental
    • Social
    • Governance
  • News & Events
  • Investors
  • Careers
  • Contact

News & Events

  • Press releases
  • In the media

Recent press releases

Evogene Reports Third Quarter 2024 Financial Results

November 21, 2024
Read full press release

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

November 19, 2024
Read full press release

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

November 12, 2024
Read full press release
All Press releases

Upcoming events

Evogene’s Special General Meeting of Shareholders

February 5, 2025
All events


Recently in the media

Vegconomist: Finally Foods Secures Funds for AI-Driven Plant Molecular Tech to Produce Casein for Cheese

April 9, 2024
Read article

Pharmaphorum: The Future of Gut Health. An interview with Biomica’s CEO, Dr. Elran Haber

March 13, 2024
Read article

The Microbiome Times: Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation

February 8, 2024
Read article

Aquaculture Magazine: Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology

November 21, 2023
Read article

AgFuder: An insightful op-ed article, by Casterra’s CEO, Eyal Ronen, discussing the potential of biofuel crops in alleviating poverty among farmers

November 19, 2023
Read article
Evogene
  • Technology
  • AI Tech-Engines
    • MicroBoost AI
    • ChemPass AI
    • GeneRator AI
  • Press
    • Press releases
    • In the media
    • Webcast
  • Investor Relations
  • About Evogene

Contact us

13 Gad Feinstein st.,
Park Rehovot,
Rehovot 7638517, Israel

Tel: 972-8-9311900
Fax: 972-8-9466724
E-mail: [email protected]

Facebook icon Linkedin icon

Copyright © 2024 Evogene Ltd.
All Rights Reserved.



CONTACT US

    INVESTOR EMAIL ALERTS

    Sign Up for Investor Relations Email Alerts






      Privacy Policy   Terms of Use   Accessibility Statement

      Designed and built by Studio Praktik